Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients, Sponsor Protocol Dated 8/11/2005 and Investigator Brochure Version August 2005

NCT00275314 is registered in ClinicalTrials.gov with University of Pittsburgh as lead sponsor.

NCT NCT00275314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00275314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients, Sponsor Protocol Dated 8/11/2005 and Investigator Brochure Version August 2005
Lead sponsor
University of Pittsburgh
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2006
Completion date
April 30, 2006
Enrollment
5
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant